Diversion Issues Sample Clauses

Diversion Issues. All Product delivered to Purchaser shall be: (a) stored securely by Purchaser; and (b) distributed by Purchaser only in Albania in a secure manner appropriate to the transportation route and destination, in each case (a) and (b) to guard against and deter theft, diversion, tampering, substitution (with, for example, counterfeits) resale or export out of Albania, and to protect and preserve the integrity and efficacy of the Product. Purchaser shall promptly notify Pfizer by email1 within 48 hours (with follow up in writing in line with the notice provisions of this Agreement) if at any time Purchaser believes that any of the Product has been stolen, diverted, tampered with, substituted, or otherwise 1Note to Draft: To include quality/diversion notice contact information. subjected to abuse, misuse, neglect, negligence, accident, improper testing, improper storage, improper handling, abnormal physical stress, abnormal environmental conditions or use contrary to any instructions issued by Pfizer. The notice shall provide all information relating to the Product diversion, including, but not limited to, detailed information including the date, time, location, number, batch number(s), expiration date, circumstances, and contact person(s) information. Purchaser shall cooperate with Pfizer or its designee, upon Pfizer’s request, to cooperate in connection with such Product diversion.
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
Diversion Issues. All Product delivered to Purchaser shall be: (a) stored securely by Purchaser; and (b) distributed by Purchaser only in Colombia in a secure manner appropriate to the transportation route and destination, in each case (a) and (b) to guard against and deter theft, diversion, tampering, substitution (with, for example, counterfeits) resale or export out of Colombia, and to protect and preserve the integrity and efficacy of the Product. Purchaser shall promptly notify Pfizer by email within 48 hours (with fo low up in writing with the notice provisions of this Agreement) if at any time Purchaser believesthat any b) Pfizer analizará las causas de tales reclamos por calidad e informará al Comprador las medidas correctivas adoptadas. Si la inspección y las pruebas de Pfizer revelan, a satisfacción razonable de Pfizer, que esos ítems del Producto constituyen Producto No Conforme y que esa no conformidad o defecto no ha sido causada o aumentada por abuso, uso indebido, descuido, negligencia, accidente, prueba, almacenamiento o manipulación indebida, tensión física o condiciones medioambientales anormales o uso contrario a cualquiera de las instrucciones impartidas por Pfizer, Pfizer empleará los Esfuerzos Comercialmente Razonables para reemplazar ese Producto No Conforme tan pronto como sea posible, sin lugar a cobro adicional al Comprador. En esas circunstancias, Pfizer gestionará la logística de recogida y destrucción del Producto No Conforme. Hasta que tenga lugar su recogida, el Comprador almacenará y mantendrá debidamente el Producto No Conforme de que se trate en lugares seguros y de acuerdo con las especificacionesde los fabricantes. No obstante, cualquier otra disposición de este Acuerdo, esta Sección 4.4(b) contempla el recurso único y exclusivo del Comprador respecto del Producto No Conforme. Las disposiciones de esta Sección 4.4 (Rechazo del Producto; Destrucción de los Envíos Rechazados) subsistirán a la terminación o vencimiento de este Acuerdo. 4.5.
Sample 1Sample 2See All (4)
Diversion Issues. Gilead agrees to immediately notify Eyetech if at any time it believes that any Product has been lost or stolen from the Facility, or any quantities of Product that have been rendered unsaleable while in Gilead's possession.
Sample 1Sample 2
Diversion Issues. Gilead shall be responsible for developing and implementing all procedures necessary to prevent the diversion of Product from the waste stream in the course of Manufacture, including the rendering of the Product unsaleable.
Sample 1Sample 2
Diversion Issues. All Product delivered to a Participating Member State shall be: (a) stored securely by the Participating Member State; and (b) without prejudice to Article I.6.2, distributed by the Participating Member State in a secure manner appropriate to the transportation route and destination, in each case (a) and (b) to guard against and deter theft, diversion, tampering, substitution (with, for example, counterfeits) or unauthorised resale or export out of the Participating Member State, and to protect and preserve the integrity and efficacy of the Product. [***]
Sample 1
Diversion Issues. Supplier shall promptly notify Customer if at any time Supplier believes that any Product Deliverable has been lost or stolen, or any Product Deliverable has been rendered unsalable.
Sample 1
Diversion Issues. All Product delivered to a Participating Member State shall be: (a) stored securely by the Participating Member State; and (b) without prejudice to Article I.6.2, distributed by the Participating Member State in a secure manner appropriate to the transportation route and destination, in each case (a) and (b) to guard against and deter theft, diversion, tampering, substitution (with, for example, counterfeits) or unauthorised resale or export out of the Participating Member State, and to protect and preserve the integrity and efficacy of the Product. [***] SANTE/2020/C3/043 - SI2.838335 SENSITIVE
Sample 1
AutoNDA by SimpleDocs
Diversion Issues. 4.6 Ustanovenia týkajúce sa presmerovania. All Product delivered to Purchaser shall be: (a) stored securely by Purchaser; and (b) without prejudice to Section Chyba! Nenašiel sa žiaden zdroj odkazov. of this Agreement, distributed by Purchaser in a secure manner appropriate to the transportation route and destination, in each case (a) and (b) to guard against and deter theft, diversion, tampering, substitution (with, for example, counterfeits) or unauthorized resale or export out of the Jurisdiction, and to protect and preserve the integrity and efficacy of the Product. Purchaser shall promptly notify Pfizer in writing (and in any event within 48 hours) if at any time Purchaser believes or becomes aware that any of the Product has been stolen, diverted, tampered with, substituted, or otherwise subjected to abuse, misuse, neglect, negligence, accident, improper testing, improper storage, improper handling, abnormal physical stress, abnormal environmental conditions or use contrary to any instructions issued by Pfizer. The notice Všetky Produkty dodávané Kupujúcemu musia byť: (a) Kupujúcim bezpečne skladované; a (b) bez toho aby bol dotknutý článok Chyba! Nenašiel sa žiaden zdroj odkazov. tejto Zmluvy, distribuované Kupujúcim bezpečným spôsobom zodpovedajúcim prepravnej trase a miestu určenia, a to v prípade (a) aj (b) tak, aby bola zaistená ochrana pred krádežou, presmerovaním, neoprávnenou manipuláciou, zámenou (napr. za falzifikáty) alebo neoprávneným ďalším predajom alebo vývozom mimo Jurisdikciu a aby bola chránená a zachovaná integrita a účinnosť Produktu. Kupujúci je povinný okamžite (v každom prípade do 48 hodín) písomne oboznámiť spoločnosť Pfizer, ak sa bude Kupujúci kedykoľvek domnievať alebo zistí, že akýkoľvek Produkt bol odcudzený, presmerovaný, bolo s ním neoprávnene manipulované, bol zamenený či bol vystavený alebo inak došlo k zneužitiu, nesprávnemu použitiu, zanedbaniu, nedbalosti, nehode, shall provide all information relating to the Product diversion, including, but not limited to, detailed information including the date, time, location, number, batch number(s), expiration date, circumstances, and contact person(s) information. Purchaser shall cooperate with Pfizer or its designee, upon Pfizer’s request, in connection with such Product diversion. Except for further distribution in the Jurisdiction permitted in accordance with this Agreement and subject to Section Chyba! Nenašiel sa žiaden zdroj odkazov. of this Agreement, Purchaser shall ...
Sample 1

Related to Diversion Issues

  • Preference Issues If any Senior Secured Party is required in any Insolvency or Liquidation Proceeding or otherwise to disgorge, turn over or otherwise pay any amount to the estate of the Company or any other Grantor (or any trustee, receiver or similar Person therefor), because the payment of such amount was declared to be fraudulent or preferential in any respect or for any other reason, any amount (a “Recovery”), whether received as proceeds of security, enforcement of any right of setoff or otherwise, then the Senior Obligations shall be reinstated to the extent of such Recovery and deemed to be outstanding as if such payment had not occurred and the Senior Secured Parties shall be entitled to the benefits of this Agreement until a Discharge of Senior Obligations with respect to all such recovered amounts. If this Agreement shall have been terminated prior to such Recovery, this Agreement shall be reinstated in full force and effect, and such prior termination shall not diminish, release, discharge, impair or otherwise affect the obligations of the parties hereto. Each Second Priority Representative, for itself and on behalf of each Second Priority Debt Party under its Second Priority Debt Facility, hereby agrees that none of them shall be entitled to benefit from any avoidance action affecting or otherwise relating to any distribution or allocation made in accordance with this Agreement, whether by preference or otherwise, it being understood and agreed that the benefit of such avoidance action otherwise allocable to them shall instead be allocated and turned over for application in accordance with the priorities set forth in this Agreement.

  • Other Issues 13.1. It is our aim to ensure a complete service at all times, but we will not be responsible when failure is caused by unforeseeable circumstances beyond our control or which we could not reasonably have foreseen.

  • Regulatory Issues 3.3.1 The Licensee shall be solely responsible for determining which jurisdictions they choose to market to and receive xxxxxx from.

  • Regulatory Investigations It shall be the Administrator’s duty and responsibility, and not the Owner Trustee’s duty and responsibility, to cause the Trust to respond to, defend, participate in or otherwise act in connection with any regulatory, administrative, governmental, investigative or other proceeding or inquiry relating in any way to the Trust, its assets or the conduct of its business.

  • Regulatory Examinations The Sub-Advisor will cooperate promptly and fully with the Advisor and/or the Trust in responding to any regulatory or compliance examinations or inspections (including information requests) relating to the Trust, the Fund or the Advisor brought by any governmental or regulatory authorities having appropriate jurisdiction (including, but not limited to, the SEC).

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Developments a) Employee will make full and prompt disclosure to Employer of all inventions, improvements, discoveries, methods, developments, software and works of authorship, whether patentable or not, which are created, made, conceived, reduced to practice by Employee or under his direction or jointly with others during his employment by Employer, whether or not during normal working hours or on the premises of Employer which relate to the business of Employer as conducted from time to time (all of which are collectively referred to in this Agreement as "Developments").

  • Tax Issues The parties agree that the payments and benefits provided under this Agreement, and all other contracts, arrangements or programs that apply to him/her, shall be subject to Section 16 of the Employment Agreement.

  • Tax Classification The Series shall elect to be treated as an association taxable as a corporation under Treasury Regulations Section 301.7701-3 with effect for each taxable period of its existence. The Series and each Member shall file all tax returns and shall otherwise take all tax and financial reporting positions in a manner consistent with such treatment. No election will be filed with the Internal Revenue Service (or the tax authorities of any State) to have the Series taxable other than as an association taxable as a corporation for income tax purposes.

Time is Money Join Law Insider Premium to draft better contracts faster.